Vertex Pharmaceuticals Simultaneous Announcements
Vertex Pharmaceuticals (VRTX) announced simultaneous presentation and publication of updated data from Phase 1/2 portion of Phase 1/2/3 FORWARD-101 clinical trial in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs).

The data were featured in oral presentation at the American Diabetes Association (ADA . . .